Detalles de la búsqueda
1.
Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.
Br J Cancer
; 117(9): 1286-1294, 2017 Oct 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-28859058
2.
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.
J Pathol
; 238(4): 562-70, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26690310
3.
FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing.
J Clin Pathol
; 76(8): 548-554, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35256486
4.
GBMdeconvoluteR accurately infers proportions of neoplastic and immune cell populations from bulk glioblastoma transcriptomics data.
Neuro Oncol
; 25(7): 1236-1248, 2023 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36689332
5.
Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer.
Clin Cancer Res
; 29(20): 4153-4165, 2023 10 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37363997
6.
Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.
JAMA Oncol
; 2(5): 633-642, 2016 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26867820
7.
Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial.
J Clin Pathol
; 69(1): 35-41, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26350752
8.
Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing.
Anal Cell Pathol (Amst)
; 34(1-2): 61-6, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21483104
Resultados
1 -
8
de 8
1
Próxima >
>>